LEXICON PHARMACEUTICALS, INC. (LXRX)

Sentiment-Signal

41,1

Bearisch

Composite Score (0–100)

Insider (25%)

75.8

2 Insider, 2,7M $ Volumen

Institutionell (22,5%)

Keine neuen Positionen

Aktivist (12,5%)

Kein 13D/13G

Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Stammdaten

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Unternehmen & Branche

Name	LEXICON PHARMACEUTICALS, INC.
Ticker	LXRX
CIK	0001062822
Boerse	US
Sektor	Healthcare
Industrie	Biotechnology
SIC	2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	671,5 Mio. USD
Beta	0,95
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	49,803,000	-50,341,000	-0.14	184,987,000	107,538,000
2025-09-30	10-Q	14,182,000	-12,769,000	-0.04	205,927,000	120,159,000
2025-06-30	10-Q	28,866,000	3,252,000	0.01	225,583,000	129,440,000
2025-03-31	10-Q	1,262,000	-25,295,000	-0.07	297,671,000	123,032,000
2024-12-31	10-K	31,081,000	-200,403,000	-0.63	298,420,000	145,950,000
2024-09-30	10-Q	1,750,000	-64,811,000	-0.18	321,123,000	178,512,000
2024-06-30	10-Q	1,647,000	-53,429,000	-0.17	373,356,000	239,980,000
2024-03-31	10-Q	1,130,000	-48,397,000	-0.20	417,219,000	288,867,000
2023-12-31	10-K	1,204,000	-177,119,000	-0.80	229,429,000	93,110,000
2023-09-30	10-Q	162,000	-50,525,000	-0.21	276,479,000	139,510,000
2023-06-30	10-Q	317,000	-44,904,000	-0.22	316,724,000	186,361,000
2023-03-31	10-Q	24,000	-31,934,000	-0.17	162,716,000	88,046,000
2022-12-31	10-K	139,000	-101,944,000	-0.62	194,299,000	117,124,000
2022-09-30	10-Q	39,000	-23,387,000	-0.13	191,685,000	144,018,000
2022-06-30	10-Q	35,000	-24,587,000		112,325,000	70,830,000
2022-03-31	10-Q		-23,476,000		136,178,000	92,698,000
2021-12-31	10-K	298,000	-87,758,000	-0.60	136,909,000	113,595,000
2021-09-30	10-Q	23,000	-23,122,000	-0.16	172,330,000	136,603,000
2021-06-30	10-Q	234,000	-18,067,000		171,672,000	137,233,000
2021-03-31	10-Q	27,000	-20,958,000		193,260,000	152,547,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2026-02-25	DEBBANE RAYMOND	Director	Open Market Purchase	2,000	1.49	2,980.00	+0,9%
2026-02-23	DEBBANE RAYMOND	Director	Open Market Purchase	100,000	1.47	147,000.00	+43,2%
2026-02-20	DEBBANE RAYMOND	Director	Open Market Purchase	100,000	1.48	147,790.00	+43,4%
2026-02-19	DEBBANE RAYMOND	Director	Open Market Purchase	50,000	1.44	71,965.00	+21,1%
2026-02-18	DEBBANE RAYMOND	Director	Open Market Purchase	133,688	1.32	176,468.16	+51,9%
2026-02-17	DEBBANE RAYMOND	Director	Open Market Purchase	76,857	1.31	100,544.33	+29,5%
2026-02-13	DEBBANE RAYMOND	Director	Open Market Purchase	57,952	1.31	75,876.55	+22,3%
2026-02-02	Invus Global Management, LLC	Director, 10% Owner	Open Market Purchase	1,538,462	1.30	2,000,000.60	+587,7%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.